Articles > Popular publications > PR Newswire press releases > April-June 2009 > Friday, April 24

Article: Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day.

Article from:
PR Newswire
Article date:
April 24, 2009
Copyright

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab

NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&D Day for investors and financial analysts at The Yale Club of New York City.

The presentations highlighted significant areas of development across Micromet's BiTE antibody platform and included updates on: 

 
  --  BiTE antibody Blinatumomab -- a rapid path to market has been 
  identified for Acute Lymphoblastic Leukemia (ALL) with a registration 
  trial planned to ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Micromet Enrolls First Patient in a Phase 1 Clinical ...
PR Newswire;  April 23, 2008 ;     700+ words ... ... most advanced BiTE antibody is MT103 (MEDI ... is the first BiTE antibody with potential ... in a phase 1 clinical trial in patients ... is the second BiTE antibody in clinical ... in a phase 1 clinical trial for the treatment ...

Article: Preclinical Study Published in Cancer Research Demonstrates ...
PR Newswire;  January 22, 2008 ;     700+ words ... ... that an EpCAM-specific BiTE antibody showed anti- tumor activities ... EpCAM are not affected by our BiTE antibody. We are now looking forward ... a human EpCAM- specific BiTE antibody, in a phase 1 clinical trial in the near future." About ...

Article: Micromet Receives European Orphan Drug Designation for Treatment ...
PR Newswire;  August 3, 2009 ;     700+ words ... ... clinical trials. Its BiTE antibody blinatumomab ... is in a phase 2 clinical trial for the treatment ... and in a phase 1 clinical trial for the treatment ... NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment ...

Article: Clinical Data Published in 'Science' Show Tumor Regressions in ...
Blood Weekly;  August 28, 2008 ;     700+ words ... ... ongoing Phase 1 clinical trial with the CD19-specific BiTE antibody blinatumomab show ... including a phase 2 clinical trial to evaluate blinatumomab ... investigating MT110, a BiTE antibody targeting EpCAM ... Company, Cancer, Clinical Trial Research, Drug ...

Article: Clinical Data Published in 'Science' Show Tumor Regressions in ...
PR Newswire;  August 14, 2008 ;     700+ words ... ... this ongoing Phase 1 clinical trial with the CD19-specific BiTE antibody blinatumomab show that ... including a phase 2 clinical trial to evaluate blinatumomab ... investigating MT110, a BiTE antibody targeting EpCAM, in ...

Article: Data Presented at ASH Annual Meeting Indicates the Potential of ...
PR Newswire;  December 8, 2008 ;     700+ words ... ... ongoing phase 2 clinical trial of blinatumomab for ALL find the BiTE antibody was able to eliminate ... lead program is a BiTE antibody known as blinatumomab ... is in a phase 2 clinical trial for the treatment ... and a phase 1 clinical trial for the ...

Article: New Data Published in Immunobiology Describe Mode of Action of ...
PR Newswire;  January 28, 2009 ;     700+ words ... ... is the second BiTE antibody in clinical ... in a phase 1 clinical trial for the treatment ... way for the BiTE antibody blinatumomab ... program is a BiTE antibody known as blinatumomab ... in a phase 2 clinical trial for the treatment ...

Article: Micromet and MedImmune Commence Treatment in Phase 2 Trial of ...
PR Newswire;  June 12, 2008 ;     700+ words ... ... ongoing phase 1 clinical trial showed potent ... activity of the BiTE antibody in patients with ... This phase 2 clinical trial in ALL is an important ... specific and potent BiTE antibody in human B cell ... and is the first BiTE antibody with potential ... is in a ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives